GlobeNewswire by notified

Brains Bioceutical Announces the Addition of Industry Veteran John Boshart to its Animal Health Division


VANCOUVER, British Columbia, May 06, 2024 (GLOBE NEWSWIRE) -- Today marks a pivotal development for Brains Bioceutical Corp ("Brains Bio"), as it significantly strengthens its Veterinary Health Division. This enhancement is led by John Boshart, a distinguished figure in animal health with profound experience from his tenures at Pfizer Animal Health and Zoetis. His arrival signifies a strategic consolidation of talent and expertise aimed at redefining standards within the veterinary sector.

Brains Bio’s Animal Health Division is empowered by the unique properties of its THC-free CBD API, which boasts an ultra-low detection limit of 0.000006%. This EU-GMP Certified API is pivotal in clinical and preclinical studies, including a Phase III Clinical Trial, highlighting its potential for therapeutic applications in veterinary medicine.

The CBD API is supported by rigorous regulatory credentials, including ICH-Q7 compliance, an actively maintained EU Active Substance Master File (ASMF), and a US Drug Master File (DMF) filed with the FDA. These certifications ensure the highest standards of quality and regulatory compliance essential for veterinary use.

The core of Brains Bio’s enhanced Veterinary Health Division lies in its focused approach to pharmaceutical development, specifically tailored to meet the nuanced needs of the animal health sector. Recognizing the unique challenges and opportunities in veterinary medicine, the division is dedicated to pioneering the development of cannabinoid-based pharmaceuticals that offer targeted, safe, and effective treatments for animals.

This strategic focus is driven by a deep understanding of the physiological and medical requirements specific to different animal species. Through rigorous research and development, combined with stringent safety and efficacy testing, Brains Bio aims to deliver a portfolio of advanced therapeutic solutions that will not only improve health outcomes but also enhance the quality of life for animals globally.

John Boshart's appointment as Vice President of Veterinary API and Business Development, reflects Brains Bio's commitment to leveraging extensive pharmaceutical expertise and cutting-edge research to advance animal health care. The division will utilize Brains Bio’s exclusive cannabinoid science combined with one of the limited global licenses to manufacture cannabinoid products specifically for veterinary use. This powerful combination of scientific acumen and legal empowerment sets a robust foundation for innovation in animal wellness and care.

Ricky Brar, CEO of Brains Bio, emphasized the strategic nature of this development: "By enhancing our Veterinary Health Division, we are not just expanding; we are redefining the role of innovative solutions in the veterinary landscape. Under the seasoned leadership of John Boshart and supported by our unmatched scientific resources, we are poised to set new benchmarks in the industry. This expansion represents a significant stride towards our vision of making a global impact by providing groundbreaking solutions to the critical health challenges facing animals worldwide."

The expansion is well-timed, as the global veterinary care market is experiencing rapid growth, driven by increased pet ownership and greater emphasis on animal health and longevity. According to a report by Grand View Research, the global animal prescription market is projected to reach approximately $58 billion by 2026. This projection underscores the vast potential and critical need for innovative health solutions within this space. Full details on the market projections can be found at: Grand View Research Report on Global Veterinary Care Market.

John Boshart shares his vision for his new role: "Leading this dynamic initiative at Brains Bio is an exhilarating opportunity to apply both my industry experience and our company’s unique capabilities toward advancing animal health care globally. Our division is uniquely positioned to spearhead significant developments in veterinary health, driven by a combination of scientific excellence, robust licensing, and strategic partnerships. The potential to transform how health care is delivered to animals is tremendous, and I am committed to ensuring we achieve substantial and meaningful impacts as well as robust growth."


Brains Bio is the leader in evidence-based and science-led pioneer of natural plant-based health and wellness solutions.

Brains Bio is a leading manufacturer of the highest quality natural and pure active pharmaceutical ingredients (APIs), with a unique suite of licenses and registrations, and is strategically positioned to take advantage of the complex regulatory environment, securing its first mover and product quality advantage. Brains Bio is diversified across the pharmaceutical, medical, and nutraceutical sectors within the rapidly growing cannabinoid market, resulting in a strong and unique value proposition.

Follow Brains Bio on Social:

Twitter: @BrainsBio, LinkedIn: @BrainsBio, Instagram: @BrainsPure

To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Iveco Group signs a 150 million euro term loan facility with Cassa Depositi e Prestiti to support investments in research, development and innovation11.6.2024 12:00:00 CEST | Press release

Turin, 11th June 2024. Iveco Group N.V. (EXM: IVG), a global automotive leader active in the Commercial & Specialty Vehicles, Powertrain and related Financial Services arenas, has successfully signed a term loan facility of 150 million euros with Cassa Depositi e Prestiti (CDP), for the creation of new projects in Italy dedicated to research, development and innovation. In detail, through the resources made available by CDP, Iveco Group will develop innovative technologies and architectures in the field of electric propulsion and further develop solutions for autonomous driving, digitalisation and vehicle connectivity aimed at increasing efficiency, safety, driving comfort and productivity. The financed investments, which will have a 5-year amortising profile, will be made by Iveco Group in Italy by the end of 2025. Iveco Group N.V. (EXM: IVG) is the home of unique people and brands that power your business and mission to advance a more sustainable society. The eight brands are each a

DSV, 1115 - SHARE BUYBACK IN DSV A/S11.6.2024 11:22:17 CEST | Press release

Company Announcement No. 1115 On 24 April 2024, we initiated a share buyback programme, as described in Company Announcement No. 1104. According to the programme, the company will in the period from 24 April 2024 until 23 July 2024 purchase own shares up to a maximum value of DKK 1,000 million, and no more than 1,700,000 shares, corresponding to 0.79% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save for the rules on share buyback programmes set out in MAR article 5) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Trading dayNumber of shares bought backAverage transaction priceAmount DKKAccumulated trading for days 1-25478,1001,023.01489,100,86026:3 June 20247,0001,050.597,354,13027:4 June 20245,0001,055.705,278,50028:6 June20243,0001,096.273,288,81029:7 June 20244,0001,106.174,424,68

Landsbankinn hf.: Offering of covered bonds11.6.2024 11:16:36 CEST | Press release

Landsbankinn will offer covered bonds for sale via auction held on Thursday 13 June at 15:00. An inflation-linked series, LBANK CBI 30, will be offered for sale. In connection with the auction, a covered bond exchange offering will take place, where holders of the inflation-linked series LBANK CBI 24 can sell the covered bonds in the series against covered bonds bought in the above-mentioned auction. The clean price of the bonds is predefined at 99,594. Expected settlement date is 20 June 2024. Covered bonds issued by Landsbankinn are rated A+ with stable outlook by S&P Global Ratings. Landsbankinn Capital Markets will manage the auction. For further information, please call +354 410 7330 or email

Relay42 unlocks customer intelligence with a new insights and reporting module, powered by Amazon QuickSight11.6.2024 11:00:00 CEST | Press release

AMSTERDAM, June 11, 2024 (GLOBE NEWSWIRE) -- Relay42, a leading European Customer Data Platform (CDP), is leveraging Amazon QuickSight to power its new real-time customer intelligence, reporting, and dashboard module. Harnessing the breadth and quality of customer data, the new Insights module empowers marketing teams to dive deep into customer behaviors and gain invaluable insights into the performance of their marketing programs across all online, offline, paid, and owned marketing channels. Preview of the Relay42 Insights module, in pre-beta version Key capabilities of the Relay42 Insights module include: Deep insights into customer behaviors: With the Relay42 Insights module, marketers can ask unlimited questions about their data and gain a deeper understanding of how to serve their customers more effectively. Simplicity with AI-powered querying: Marketers can use artificial intelligence to query their data using natural language search, reducing the reliance on data scientists. Us

Metasphere Labs Announces X Spaces Event on the Topic of Green Bitcoin Mining and Sound Money for Sustainability11.6.2024 10:30:00 CEST | Press release

VANCOUVER, British Columbia, June 11, 2024 (GLOBE NEWSWIRE) -- Metasphere Labs Inc. (formerly Looking Glass Labs Ltd., "Metasphere Labs" or the "Company") (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is thrilled to announce an engaging Twitter Spaces event on Green Bitcoin mining, energy markets, and sustainability on July 3, 2024 at 2 p.m. ET. Follow us on X at MetasphereLabs for updates and to join the event. What We'll Discuss Bitcoin Mining Basics: Understand the fundamentals of Bitcoin mining.Energy Market Dynamics: Explore how Bitcoin mining interacts with energy markets.Sustainable Innovations: Learn about our efforts to promote sustainability in Bitcoin mining.Sound Money: Discover how tamper-proof currency can enhance stability.Efficient Payment Rails: See how fast, neutral payment systems support humanitarian projects.Carbon Footprint: Compare Bitcoin's environmental impact with traditional banking. "We're excited to host this event and dive into the critical topics of Bitcoin

HiddenA line styled icon from Orion Icon Library.Eye